Bonus Biogroup Stock Current Valuation
| BBIXF Stock | USD 0.02 0.00 0.00% |
Valuation analysis of Bonus BioGroup helps investors to measure Bonus BioGroup's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Bonus BioGroup's price fluctuation is out of control at this time. Calculation of the real value of Bonus BioGroup is based on 3 months time horizon. Increasing Bonus BioGroup's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bonus pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Bonus BioGroup. Since Bonus BioGroup is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bonus Pink Sheet. However, Bonus BioGroup's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.02 | Real 0.02 | Hype 0.02 | Naive 0.0203 |
The real value of Bonus Pink Sheet, also known as its intrinsic value, is the underlying worth of Bonus BioGroup Company, which is reflected in its stock price. It is based on Bonus BioGroup's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bonus BioGroup's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bonus BioGroup helps investors to forecast how Bonus pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bonus BioGroup more accurately as focusing exclusively on Bonus BioGroup's fundamentals will not take into account other important factors: Bonus BioGroup Company Current Valuation Analysis
Bonus BioGroup's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bonus BioGroup Current Valuation | 48.99 M |
Most of Bonus BioGroup's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus BioGroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bonus BioGroup has a Current Valuation of 48.99 M. This is 99.66% lower than that of the Healthcare sector and 98.95% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.71% higher than that of the company.
Bonus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bonus BioGroup's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bonus BioGroup could also be used in its relative valuation, which is a method of valuing Bonus BioGroup by comparing valuation metrics of similar companies.Bonus BioGroup is currently under evaluation in current valuation category among its peers.
Bonus Fundamentals
| Return On Equity | -0.55 | |||
| Return On Asset | -0.0636 | |||
| Current Valuation | 48.99 M | |||
| Shares Outstanding | 1.17 B | |||
| Shares Owned By Insiders | 49.72 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.05 X | |||
| EBITDA | (88.03 M) | |||
| Net Income | (90.08 M) | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 9.13 X | |||
| Cash Flow From Operations | (39.84 M) | |||
| Beta | 1.4 | |||
| Market Capitalization | 62.59 M | |||
| Total Asset | 104.32 M | |||
| Net Asset | 104.32 M |
About Bonus BioGroup Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bonus BioGroup's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bonus BioGroup using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bonus BioGroup based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Bonus Pink Sheet
Bonus BioGroup financial ratios help investors to determine whether Bonus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus BioGroup security.